ArticlePloS one2025
Clarification of fibrin generation and degradation reaction processes of clot-fibrinolysis waveform in hemorrhagic disorders.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clot-fibrinolysis waveform analysis (CFWA) is an assay used to simultaneously evaluate coagulation and fibrinolysis reactions. Although the assay detected the reaction via transmittance changes, there was no evidence that the transmittance changes indicated reactions. This study aimed to demonstrate that transmittance changes indicate coagulation and fibrinolysis reactions by detecting relative markers. CFWA was conducted using activated partial thromboplastin time (APTT) reagent and CaCl2 solution with tissue-plasminogen activator (tPA); transmittance changes were monitored, and the first derivative curve was analyzed in pooled normal plasma (PNP) and factors V, VIII, IX, X, and XI-deficient plasma samples. The samples during the coagulation and fibrinolysis reactions were prepared by adding the reaction stop solution, fibrin monomer complex (FMC), fibrin/fibrinogen degradation products (FDP), D-dimer and plasmin-α2 plasmin inhibitor complex (PAP) were measured to compare the waveform with the tendencies of these markers. The fibrinolysis markers FDP, D-dimer, and PAP increased in all samples as the reaction time increased. In FMC, the value increased during the coagulation phase, decreased at the end of the phase, and increased again during the fibrinolysis phase. FMC, FDP, and D-dimers were generated from fibrin/fibrinogen in the CFWA assay, indicating that the assay reflects coagulation and fibrinolysis reactions by monitoring transmittance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.